JKT · MARK.JK
PT Mark Dynamics Indonesia Tbk
IDR 1,150+IDR 65 (+5.99%)
PT Mark Dynamics Indonesia Tbk’s quoted price sits in the upper half of its reported 52-week range, 9.09% below the high.
Loading market information…
JKT · MERK.JK · IDR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:03 AM UTC. Cached market data; not a live quote.
One-year closing-price history · IDR. Historical prices are not a forecast.
PT Merck Tbk’s quoted price sits in the lower half of its reported 52-week range, 19.78% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
PT Merck Tbk’s forward annual dividend is IDR 275 per share, paid annual. The forward yield is 7.62% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow PT Merck Tbk’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating in Indonesia, PT Merck Tbk is a pharmaceutical company focused on the production and distribution of medicinal products. Its business operations are structured into three main divisions: Biopharma, Consumer Health, and an 'Others' segment. The company provides healthcare solutions addressing a broad spectrum of therapeutic areas, including conditions related to the cardiovascular system, metabolism, oncology, endocrinology, fertility, and neurodegenerative disorders, alongside general pharmaceutical offerings. Furthermore, PT Merck Tbk is actively involved in the discovery, development, production, and commercialization of both pharmaceutical and biological prescription drugs. These medicines target specific conditions such as colorectal and head and neck cancers, multiple sclerosis, infertility, growth hormone imbalances, diabetes, and various thyroid conditions like hyperthyroidism and hypothyroidism. Beyond its core pharmaceutical activities, the company also engages in property leasing and management. Established in 1970 and headquartered in East Jakarta, Indonesia, the company was originally known as PT Merck Indonesia Tbk before adopting its current name, PT Merck Tbk, in June 2002. It operates as a subsidiary of Merck Holding GmbH.
Latest available per-share figures in IDR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:36 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
IDR 1,150+IDR 65 (+5.99%)
PT Mark Dynamics Indonesia Tbk’s quoted price sits in the upper half of its reported 52-week range, 9.09% below the high.
IDR 3,600-IDR 40 (-1.1%)
PT Prodia Widyahusada Tbk’s quoted price sits in the upper half of its reported 52-week range, 4.26% below the high.
IDR 1,570IDR 0 (0.0%)
PT Darya-Varia Laboratoria Tbk’s quoted price sits in the upper half of its reported 52-week range, 7.37% below the high.
IDR 195+IDR 2 (+1.04%)
PT Bundamedik Tbk’s quoted price sits in the lower half of its reported 52-week range, 20.73% below the high.
IDR 350-IDR 4 (-1.13%)
PT Itama Ranoraya Tbk’s quoted price sits in the lower half of its reported 52-week range, 43.09% below the high.
IDR 123-IDR 2 (-1.6%)
UBC Medical Indonesia Tbk.’s quoted price sits in the lower half of its reported 52-week range, 52.69% below the high.
IDR 64-IDR 4 (-5.88%)
PT Maja Agung Latexindo Tbk’s quoted price sits in the lower half of its reported 52-week range, 44.83% below the high.
IDR 278-IDR 2 (-0.71%)
PT Diagnos Laboratorium Utama Tbk’s quoted price sits in the upper half of its reported 52-week range, 27.23% below the high.
